January 18, 2012 — Topline results of a phase 3 trial of dimebon, also called latrepirdine, on top of ongoing treatment with donepezil has shown no benefit in patients with mild to moderate Alzheimer’s disease (AD). The companies developing dimebon in this indication, Medivation Inc and Pfizer Inc, issued a joint statement noting that results [...]
9.13.2010 Protein-Based Biomarkers in Blood Serum Could Classify Individuals With Alzheimer's Disease Archives of Neurology, JAMA An initial analysis suggests that biomarkers in blood serum can be combined with clinical information to accurately classify patients with Alzheimer’s disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.
7.25.2010 Texas Scientists on Verge of Alzheimer's Blood Test Houston Chronicle Todd Ackerman reports the latest on how TARC scientists say exam would help millions confirm & fight the disease
7.16.2010 Alzheimer's Screen May Be Possible Lubbock Avalanche-Journal Sid O'Bryant, an assistant professor of neurology, has published the first step in developing a blood test for Alzheimer's disease.
7.13.2010 Texas Researchers Announce Breakthrough In Alzheimer's Research New Procedure Allows Diagnosis with Simple Blood Test
4.09.2010 TARC Distinguished Speakers Announced For the First Ever “Meeting of the Minds” - The Texas State Plan on Alzheimer’s Disease Public Input Meeting & Scientific Symposium
4.01.2010 UT Medicine San Antonio Physicians at Forefront of Alzheimer's Research The Mission Psychiatrist Donald R. Royall, M.D., and neurologist Gustavo C. Roman, M.D., are recruiting 500 Hispanics age 59 or older for a longitudinal study that will attempt to determine the prevalence of Alzheimer's in the Hispanic population and pinpoint risk factors.
4.10.2010 A Drug that Extends Life Span Prevents Alzheimer's Deficits UTHSC News
11.10.2009 UT Southwestern Medical Center Dallas Recruiting for Clinical Trials.
5.18.2010 Changing the Trajectory of Alzheimer's Disease: A National Imperative Alzheimer's Association This report examines the current projections and costs associated with the Alzheimer crisis, as well as what Medicare and Medicaid savings are possible if disease modifying treatments were available.